Small Cell Lung Cancer

Neil Basumallik, Manuj Agarwal, Neil Basumallik, Manuj Agarwal

Excerpt

Lung cancer is the second most diagnosed cancer in the United States. It is the leading cause of cancer death in both men and women, accounting for approximately a quarter of all cancer deaths. Lung cancer is histologically divided into 2 main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC comprises about 15% of lung cancer while NSCLC comprises approximately 85%. Since the late 1980s, there has been a decline in the incidence of lung cancer coincident with a decline in smoking, the leading cause of lung cancer. Current treatments include surgery, chemotherapy, radiotherapy, and immunotherapy. The high incidence and prevalence of lung cancer provide a foundation for new insights into the role of public health interventions, genetics, and novel treatment modalities.

Conflict of interest statement

Disclosure: Neil Basumallik declares no relevant financial relationships with ineligible companies.

Disclosure: Manuj Agarwal declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

References

    1. Ju MH, Kim HR, Kim JB, Kim YH, Kim DK, Park SI. Surgical outcomes in small cell lung cancer. Korean J Thorac Cardiovasc Surg. 2012 Feb;45(1):40-4.
    1. Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol. 2012 Jan;25 Suppl 1:S18-30.
    1. Wilcox HB, Al-Zoughool M, Garner MJ, Jiang H, Klotz JB, Krewski D, Nicholson WJ, Schoenberg JB, Villeneuve PJ, Zielinski JM. Case-control study of radon and lung cancer in New Jersey. Radiat Prot Dosimetry. 2008;128(2):169-79.
    1. Parent ME, Siemiatycki J, Renaud G. Case-control study of exposure to carbon black in the occupational setting and risk of lung cancer. Am J Ind Med. 1996 Sep;30(3):285-92.
    1. Myers DJ, Wallen JM. StatPearls [Internet] StatPearls Publishing; Treasure Island (FL): 2023. Jun 12, Lung Adenocarcinoma.
    1. Rybarczyk-Kasiuchnicz A, Ramlau R. Current views on molecularly targeted therapy for lung cancer - a review of literature from the last five years. Kardiochir Torakochirurgia Pol. 2018 Jun;15(2):119-124.
    1. Oh IJ, Hur JY, Park CK, Kim YC, Kim SJ, Lee MK, Kim HJ, Lee KY, Lee JC, Choi CM. Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma. Clin Lung Cancer. 2018 Sep;19(5):e775-e781.
    1. Moon SH, Kim J, Joung JG, Cha H, Park WY, Ahn JS, Ahn MJ, Park K, Choi JY, Lee KH, Kim BT, Lee SH. Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):446-454.
    1. Morita S, Suda T, Oda C, Kobayashi M, Hoshi T, Kanefuji T, Yagi K, Hasegawa G, Terai S. The Value of 18F-FDG PET in the Diagnosis of Intertrabecular Vertebral Metastasis in a Small Cell Lung Cancer Patient with a High Serum CEA Level. Intern Med. 2019 Feb 01;58(3):415-418.
    1. Duffy MJ, O'Byrne K. Tissue and Blood Biomarkers in Lung Cancer: A Review. Adv Clin Chem. 2018;86:1-21.
    1. Iqbal MA, Arora S, Prakasam G, Calin GA, Syed MA. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 2019 Dec;70:3-20.
    1. Eze C, Roengvoraphoj O, Schmidt-Hegemann NS, Käsmann L, Dantes M, Manapov F. Chemoradiotherapy of stage III small-cell lung cancer: Can we further optimize multimodal treatment of N3 disease based on current evidence? Clin Respir J. 2018 Oct;12(10):2534-2535.
    1. Dickhoff C, Rodriguez Schaap PM, Otten RHJ, Heymans MW, Heineman DJ, Dahele M. Salvage surgery for local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review. Ther Adv Med Oncol. 2018;10:1758835918787989.
    1. Qin J, Lu H. Combined small-cell lung carcinoma. Onco Targets Ther. 2018;11:3505-3511.
    1. Mitin T, Jain A, Degnin C, Chen Y, Henderson M, Thomas CR. Current patterns of care for patients with extensive stage small cell lung cancer: Survey of US radiation oncologists on their recommendations regarding thoracic consolidation radiotherapy. Lung Cancer. 2016 Oct;100:85-89.
    1. Kalemkerian GP. Running in Place: The 20th Anniversary of the NCCN Small Cell Lung Cancer Guidelines Panel. J Natl Compr Canc Netw. 2015 Jun;13(6):704-6.
    1. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW, Merritt RE, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC, Gregory K, Hughes M, National Comprehensive Cancer Network Small cell lung cancer. J Natl Compr Canc Netw. 2013 Jan 01;11(1):78-98.
    1. Sone H, Igawa S, Kasajima M, Ishihara M, Hiyoshi Y, Hosotani S, Ohe S, Ito H, Kaizuka N, Manaka H, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K. Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study. Thorac Cancer. 2018 Oct;9(10):1279-1284.
    1. Engelhardt KE, Feinglass JM, DeCamp MM, Bilimoria KY, Odell DD. Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time-trend analysis of the National Cancer Data Base. J Thorac Cardiovasc Surg. 2018 Sep;156(3):1233-1246.e1.
    1. Nakamura M, Onozawa M, Motegi A, Hojo H, Zenda S, Nakamura N, Udagawa H, Kirita K, Matsumoto S, Umemura S, Yoh K, Niho S, Goto K, Akimoto T. Impact of prophylactic cranial irradiation on pattern of brain metastases as a first recurrence site for limited-disease small-cell lung cancer. J Radiat Res. 2018 Nov 01;59(6):767-773.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다